The Paris Life Sciences team advised Alven in the €32 million Series A financing of Verley, a nutrition-focused ingredient company developing high-performance whey proteins through precision fermentation.
The round was led by Alven and included Blast and Bpifrance alongside longstanding investors Sofinnova, Sparkfood, Captech Santé, and Founders Future.
The funding will support Verley's expansion into the US market, including the launch of its commercial operations, the development of initial customer partnerships and the scaling of its production capacity.
Based in Lyon, Verley develops ingredients for the food and nutrition industries. Through precision fermentation, the company produces high-performance whey proteins with specific functional properties designed to deliver the nutritional and technical performance expected by food and nutrition manufacturers seeking sustainable, high-performance solutions.
The Goodwin team included Anne-Charlotte Rivière, Louis Taslé d'Heliand, and Joséphine Remoussenard on corporate aspects as well as Marie Fillon and Albana Taipi on IP aspects.